Competing interests
Masitinib is under clinical development by the study funder, AB Science. AM, OH, and CDM are employees and shareholders of AB Science. BD reports consultant fees from AB Science and Biogen and an institutional grant from Roche and Foundation Merck-Avenir. PV reports honoraria and consulting fees from Biogen, Sanofi-Genzyme, Novartis, Teva, Merck, Roche, Celgene, Imcyse, and AB Science; and research grants from Sanofi-Genzyme, Roche, and Merck. All remaining authors have no competing interests.